newsfilter
← Latest News
GlobeNewswire·

Belite Bio Reports Unaudited Second Quarter 2026 Financial Results and Provides a Corporate Update

U.S. Food and Drug Administration (FDA) accepted the New Drug Application (NDA) with Priority Review for tinlarebant for the treatment of Stargardt disease type 1 (STGD1); Prescription Drug User Fee Act (PDUFA) target